Because of price discrimination, Europeans pay much more for GlaxoSmithKline's (GSK) AIDS drug Combivir than do Africans. If price discrimination were outlawed and GSK had to choose one price for both markets, this could: benefit Europeans in the long run, because GSK's higher profits might increase its incentives to develop new drugs. harm Europeans in the short run, because GSK might choose a world price that is higher than the European price. benefit Europeans in the short run, because GSK might choose a world price that is lower than the African price. harm Europeans in the long run, because GSK's lower profits might reduce its incentives to develop new drugs